Literatur

  1. Konstantinides SV et al.: 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2014; 35(43): 3033-69, 3069a-3069k
  2. Wells PS et al.: Does this patient have deep vein thrombosis? JAMA 2006; 295(2): 199-207
  3. Kearon C et al.: Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149(2): 315-52
  4. Beyer-Westendorf J, Ageno W: Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thromb Haemost 2015; 113(2): 231-46
  5. Agnelli G et al.: Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369(9): 799-808
  6. Büller HR et al.: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366(14): 1287-97
  7. Jiménez D et al: Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170(15): 1383-9
  8. Kyrle PA et al.: The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study. J Thromb Haemost 2016; 14(12): 2402-9
  9. Agnelli G et al.: Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368(8): 699-708
Pfad: